Platelet counts and subgroup analyses. Median platelet counts (IQR) over time for rilzabrutinib vs placebo arms (A) and by responder status (B), and subgroup analysis of durable responses (C). Durable platelet response was defined as the proportion of patients achieving platelet counts of ≥50 × 109/L for two-thirds or more of at least 8 nonmissing weekly scheduled platelet measurements during the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy, provided that at least 2 nonmissing weekly platelet measurements were ≥50 × 109/L during the last 6 weeks of the 24-week blinded treatment period. Vertical dashed line at week 13 represents measurement of patient response and continuation of responders to treatment through 24 weeks. IQR, interquartile range; y, year.
